Edwards Lifesciences (NYSE:EW) VP Daniel Lippis Sells 1,019 Shares of Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 1,019 shares of the business’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $85.70, for a total value of $87,328.30. Following the completion of the transaction, the vice president owned 22,002 shares of the company’s stock, valued at $1,885,571.40. This represents a 4.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Edwards Lifesciences Trading Up 0.7%

Edwards Lifesciences stock opened at $85.14 on Friday. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.89. The business’s fifty day moving average is $85.06 and its 200 day moving average is $80.32. The stock has a market capitalization of $49.41 billion, a PE ratio of 36.70, a price-to-earnings-growth ratio of 3.44 and a beta of 0.95. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The business’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on EW. The Goldman Sachs Group reissued a “buy” rating and set a $108.00 price target on shares of Edwards Lifesciences in a report on Friday. Raymond James Financial upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price objective for the company in a research report on Monday, November 3rd. JPMorgan Chase & Co. raised Edwards Lifesciences from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $90.00 to $100.00 in a research report on Thursday, December 18th. Jefferies Financial Group set a $98.00 price target on Edwards Lifesciences and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, Citigroup reiterated a “buy” rating and issued a $101.00 price objective (up previously from $96.00) on shares of Edwards Lifesciences in a research note on Thursday, December 11th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average target price of $94.57.

Institutional Investors Weigh In On Edwards Lifesciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Norges Bank purchased a new position in Edwards Lifesciences during the second quarter valued at $580,640,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in shares of Edwards Lifesciences by 111.2% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock valued at $714,006,000 after purchasing an additional 4,805,819 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Edwards Lifesciences by 278.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after purchasing an additional 4,108,270 shares during the last quarter. Marshall Wace LLP grew its position in shares of Edwards Lifesciences by 127.5% during the second quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock valued at $539,303,000 after purchasing an additional 3,864,908 shares in the last quarter. Finally, Viking Global Investors LP bought a new stake in shares of Edwards Lifesciences in the third quarter worth about $238,688,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.